Most Read Articles
31 May 2016
Tacrolimus is safe and effective in inducing and maintaining remission in paediatric patients with biologic refractory inflammatory bowel disease (IBD), according to a study presented at the 49th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition in Athens, Greece.
Rachel Soon, 12 Dec 2018

MIMS Pharmacist presents an overview of superoxide dismutase (SOD) and its role in resisting the effects of oxidative stress and aging.

Rachel Soon, 25 Jul 2018

MIMS Pharmacist presents an overview of Lactobacillus plantarum 299v's physiological role, as well as contemporary research on its pharmacology and effects.

01 Mar 2018
Lifetime prevalence of acute pain leading to the use of analgesics approaches 100% in the general population, and pharmacists are a pivotal first point of contact for patients in their journey to better pain management. Noting the need for pharmacists to be more aware of their evolving role as a community pharmacist, GlaxoSmithKline Consumer Healthcare partnered with MIMS Education to organize a workshop that served as a platform for robust knowledge-sharing. Below are highlights from the workshop.

Product Highlight – Dukoral

12 Jul 2017
DUKORAL – Inactivated Vibrio cholerae O1 serogroup & recombinant cholera toxin B subunit (WC/rCTB) vaccine (oral) – AJ Biologics

The Drinkable Vaccine against Cholera & enterotoxigenic E.coli (ETEC) Diarrhoea


Clinically proven protective efficacy:
- Up to 85-90% against cholera in the first 6 months3,4,6
- Up to 67% against ETEC in the first 3 months.5

At least one week interval between doses. Primary immunization can be completed as early as 8 days for adults and children over 6 years old (2 required doses) and 15 days for children 2-6 years (3 required doses).1

Onset of protection starts 7 days after completion of immunisation. The vaccination course should be completed at least one week before traveling.1

Good safety profile with most frequently reported adverse reactions occurred at similar frequencies in vaccine and placebo group in studies.

References:

1. DUKORAL full prescribing information (SV40398_MY).
2. Clements JD, Finkelstein RA. Demonstration of shared and unique immunological determinants in enterotoxins from Vibrio cholerae and Escherichia coli. Infect Immun 1978;22:709–13.
3. World Health Organization. Use of Oral Cholera Vaccine in Humanitarian Emergencies. http://www.who.int/cholera/vaccines/OCV_in_humanitarian_emergencies_15Jan2014.pdf.
4. Clemens JD, Sack DA, Harris RJ et al. Field trial of oral cholera vaccines in Bangladesh. Lancet 1986, 2:124-7.
5. Clemens JD., et al. Cross-protection by B subunit whole-cell cholera vaccine against diarrhoea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: result of a large-scale field trial. J Infect Dis 1988; 158:372-77.
6.
World Health Organization. Cholera vaccines WHO position paper. Weekly Epidemiologic Record (WER). No 13, 2010, 85, 117-128 http://www.who.int/wer/2010/wer8513.pdf.

Further information is available in section 12b, New in This Issue and mims.com
Full prescribing information is available upon request.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
31 May 2016
Tacrolimus is safe and effective in inducing and maintaining remission in paediatric patients with biologic refractory inflammatory bowel disease (IBD), according to a study presented at the 49th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition in Athens, Greece.
Rachel Soon, 12 Dec 2018

MIMS Pharmacist presents an overview of superoxide dismutase (SOD) and its role in resisting the effects of oxidative stress and aging.

Rachel Soon, 25 Jul 2018

MIMS Pharmacist presents an overview of Lactobacillus plantarum 299v's physiological role, as well as contemporary research on its pharmacology and effects.

01 Mar 2018
Lifetime prevalence of acute pain leading to the use of analgesics approaches 100% in the general population, and pharmacists are a pivotal first point of contact for patients in their journey to better pain management. Noting the need for pharmacists to be more aware of their evolving role as a community pharmacist, GlaxoSmithKline Consumer Healthcare partnered with MIMS Education to organize a workshop that served as a platform for robust knowledge-sharing. Below are highlights from the workshop.